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Abstract
Background: Animal and clinical studies have revealed that focal peripheral nerve axon demyelination is accompanied
by nociceptive pain behavior. C-C and C-X-C chemokines and their receptors have been strongly implicated in
demyelinating polyneuropathies and persistent pain syndromes. Herein, we studied the degree to which chronic
nociceptive pain behavior is correlated with the neuronal expression of chemokines and their receptors following
unilateral lysophosphatidylcholine (LPC)-induced focal demyelination of the sciatic nerve in rats.
Results:  Focal nerve demyelination increased behavioral reflex responsiveness to mechanical stimuli between
postoperative day (POD) 3 and POD28 in both the hindpaw ipsilateral and contralateral to the nerve injury. This
behavior was accompanied by a bilateral increase in the numbers of primary sensory neurons expressing the chemokine
receptors CCR2, CCR5, and CXCR4 by POD14, with no change in the pattern of CXCR3 expression. Significant
increases in the numbers of neurons expressing the chemokines monocyte chemoattractant protein-1 (MCP-1/CCL2),
Regulated on Activation, Normal T Expressed and Secreted (RANTES/CCL5) and interferon γ-inducing protein-10 (IP-
10/CXCL10) were also evident following nerve injury, although neuronal expression pattern of stromal cell derived
factor-1α (SDF1/CXCL12) did not change. Functional studies demonstrated that acutely dissociated sensory neurons
derived from LPC-injured animals responded with increased [Ca2+]i following exposure to MCP-1, IP-10, SDF1 and
RANTES on POD 14 and 28, but these responses were largely absent by POD35. On days 14 and 28, rats received either
saline or a CCR2 receptor antagonist isomer (CCR2 RA-[R]) or its inactive enantiomer (CCR2 RA-[S]) by
intraperitoneal (i.p.) injection. CCR2 RA-[R] treatment of nerve-injured rats produced stereospecific bilateral reversal
of tactile hyperalgesia.
Conclusion: These results suggest that the presence of chemokine signaling by both injured and adjacent, uninjured
sensory neurons is correlated with the maintenance phase of a persistent pain state, suggesting that chemokine receptor
antagonists may be an important therapeutic intervention for chronic pain.
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Introduction
Inflammatory events induced by nerve injury are thought
to play a central role in the pathogenesis of inflammatory
pain. The production and release of molecules that medi-
ate the acute inflammatory response include bradykinin,
tachykinins, serotonin, histamine, ATP and cytokines
such as tumor necrosis factor-alpha (TNFα), interleukin
1-β (IL-1β), and interleukin-6 (IL-6). Many of these mol-
ecules, which are produced in association with acute
inflammatory responses, are known to induce hyperalge-
sia [1,2]
Chemokines, which also contribute to the development
of inflammatory pain states, can directly excite subsets of
sensory neurons [3-8]. This excitation is likely to be due to
transactivation of ion channels, such as TRPV1 and
TRPA1, expressed by sensory nerves [9,10]. As such, it is
quite possible that a prolonged de novo expression of
chemokines and/or their cognate receptors by sensory
neurons following peripheral nerve injury may be central
to the development and/or maintenance of chronic pain
states. Indeed, we previously demonstrated that in a
rodent model of spinal stenosis, chronic compression of
the DRG (CCD), produced a delayed but chronic expres-
sion of both the chemokine receptor CCR2 and its ligand,
the chemokine MCP-1/CCL2 in lumbar DRGs [8]. Fur-
thermore, MCP-1/CCL2 depolarized or increased the
excitability of several subpopulations of sensory neurons,
including nociceptors, in both the intact and dissociated
DRG [6,8]. Interestingly, mice deficient in the chemokine
receptor, CCR2, exhibit an impaired neuropathic pain
response following partial nerve ligation [11].
In order to fully understand the extent and significance of
neuronal chemokine signaling in states of pain hypersen-
sitivity, we examined whether induction of a focal demy-
elination of the sciatic nerve, a known rodent model of
neuropathic pain [12], produced changes in the neuronal
expression of certain key chemokines previously shown to
be extensively upregulated in peripheral neuroinflamma-
tory responses [3,13-16]. These chemokines included
monocyte chemoattractant protein-1 (MCP-1/CCL2),
interferon γ-inducing protein-10 (IP-10/CXCL10), regu-
lated on activation normal T cell expressed and released
(RANTES/CCL5) and stromal cell derived factor-1 (SDF1/
CXCL12) and their cognate receptors (CCR2, CXCR3,
CCR5 and CXCR4, respectively).
We now demonstrate that focal peripheral nerve demyeli-
nation in the right thigh of the rat produces chronic bilat-
eral nociceptive behavior as measured by hindpaw
withdrawal. Together with the ongoing display of nocice-
ptive behavior is a delayed upregulation of several C-C
and C-X-C chemokines and their cognate receptors by sen-
sory neurons. Though there is an initial delay in ligand/
receptor upregulation, the continued expression of neuro-
nal chemokine/receptors appears to correlate with
changes in chronic nociceptive behavior. Furthermore,
administration of a CCR2 receptor antagonist produced
an attenuation of the nociceptive behavior, further high-
lighting the potential role of chemokine signaling in states
of neuropathic pain.
Parts of this study have been previously published in
abstract form [17,18].
Methods
Animals
Pathogen-free, adult female Sprague-Dawley rats
(150–200 g; Harlan Laboratories, Madison, WI) were
housed in temperature (23 ± 3°C) and light (12-h
light:12-h dark cycle; lights on at 07:00 h) controlled
rooms with standard rodent chow and water available ad
libitum. Experiments were performed during the light
cycle. Animals were randomly assigned to the treatment
groups. These experiments were approved by the Institu-
tional Animal Care and Use Committee of Loyola Univer-
sity, Chicago. All procedures were conducted in
accordance with the Guide for Care and Use of Laboratory
Animals published by the National Institutes of Health
and the ethical guidelines of the International Association
for the Study of Pain. All animals were randomly assigned
to either treatment or control groups.
Sciatic nerve demyelination
Animals were anesthetized with 4% isoflurane and main-
tained on 2% isoflurane (Halocarbon, River Edge, NJ) in
O2. For all demyelination experiments, lysophosphatidyl-
choline (LPC), (type V, 99% pure; Sigma-Aldrich, St.
Louis, MO) was dissolved in buffered sterile saline (pH
7.2) to give a final concentration of 10 mg/ml. The right
sciatic nerve of the rat was exposed at the mid-thigh level
under sterile conditions. A sterile polyvinyl acetal (PVAc)
sponge (Ivalon, San Diego, CA), 2-mm × 2-mm soaked in
7 μl of LPC, was placed adjacent to the sciatic nerve. The
dermal incision site was closed with 5.0 suture thread.
Sham control animals were prepared as described above,
but buffered sterile saline was used in place of LPC plus
saline. Some control rats were also given an intramuscular
injection of LPC (10 ul, 1%) into the gastrocnemius mus-
cle.
Drugs and method of administration
A CCR2 receptor antagonist and its inactive enantiomer
were employed in this study [19]. The CCR2 antagonist
active enantiomer's full name is (R)-4-Acetyl-1-(4-chloro-
2-fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-
2H-pyrrol-2-one (CCR2 RA [R]). The inactive enantiomer
is (S)-4-Acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-
3-hydroxy-1,5-dihydro-2H-pyrrol-2-one (CCR2 RA [S])Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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(Additional file 1). Both were employed as Na+ salts. The
affinity of CCR2 RA [R] for the rat CCR2 receptor is >
4000 that of the S-isomer. Both compounds were freshly
prepared in saline on the day of the experiment (10 mg/
kg). Active and inactive enantiomer and vehicle-treated
groups (n = 8 per group) were given a one-time intraperi-
toneal (i.p.) injection one hour prior to behavioral test-
ing.
Foot withdrawal to punctate mechanical indentation
The incidence of foot withdrawal was measured in
response to mechanical indentation of the plantar surface
of each hind paw with sharp, Von Frey-type nylon fila-
ments. Mechanical stimuli were applied with seven fila-
ments, each differing in the bending force delivered (10,
20, 40, 60, 80, 100, and 120 mN), but each fitted with the
same metal cylinder with a flat tip and a fixed diameter of
0.2 mm [3]. In each behavioral testing sequence, the oper-
ator was blinded to the animal treatment condition.
The rat was placed on a metal mesh floor and covered
with a transparent plastic dome. Typically, the animals
rest quietly in this situation after an initial few minutes of
exploration. Animals were habituated to this testing appa-
ratus for 15 minutes a day, two days prior to the behavio-
ral assays. Following acclimation, each filament was
applied to six spots spaced across the hind paw. The fila-
ments were tested in order of ascending force, with each
filament delivered in sequence from the 1st to the 6th spot
alternating from one hind paw to the other. The duration
of each stimulus was 1 second and the interstimulus inter-
val was 10–15 seconds. A cutoff value of 120 mN was
used; animals that did not respond at 120 mN were
assigned that value [3,20].
The incidence of foot withdrawal was expressed as a per-
centage of the six applications of each filament as a func-
tion of force. A Hill equation was fitted to the function
(Origin version 6.0, Microcal Software, Northhampton
MA) relating the percentage of indentations eliciting a
withdrawal to the force of indentation. From this equa-
tion, the paw withdrawal threshold (PWT) force was
obtained and defined as the force corresponding to a 50%
withdrawal. At least a -20 mN difference from the baseline
PWT in a given animal is representative of neuropathic
pain [3].
Measurements were taken on three successive days before
surgery. Postoperative testing was performed on one,
three and seven days after surgery and weekly thereafter
for the duration of the experiment. PWT values were sta-
tistically analyzed for each foot separately and for the sig-
nificance of differences between the average of the three
preoperative tests and the mean obtained for each postop-
erative test. The same statistical analyses are applied to the
slopes of the logistic functions from which the PWTs are
derived. The experimenter was blinded to both the injury
condition of the animal and the drugs utilized in all
behavioral trials.
Foot withdrawal to thermal stimulus
To evaluate the PWT to thermal stimulation, we used the
Hargreaves' plantar test apparatus (Ugo Basile, Varese,
Italy). Rats were placed on a 2-mm-thick glass floor; a
mobile infrared heat generator with an aperture of 10 mm
was aimed at the rat's hind paw under the floor. Following
activation of the heat source, the reaction time (the with-
drawal latency of the hindpaw) of the rat was recorded
automatically. A shortening of the withdrawal latency
indicated thermal hyperalgesia. The temperature of the
glass floor was kept at 22.5–23.5°C. Measurements of the
withdrawal latency of the paw began after the rats were
habituated to the testing environment (IR setting = 70).
The measurements were repeated four times, at 5 min
intervals, on each paw, and the initial pair of measure-
ments was not used. The averages of the three remaining
pairs of measurements taken were employed as data.
In situ hybridization
In situ hybridization histochemistry for chemokine recep-
tors was performed by using digoxigenin-labeled ribo-
probes. Adult female Sprague-Dawley rats were
euthanized using carbon dioxide. L4L5 DRGs ipsi- and
contralateral to LPC nerve injury were rapidly removed,
embedded in OCT compound (Tissue Tek, Ted Pella, Inc.,
Redding, CA) and frozen. Sections were serially cut at 14
μm. The CCR2 probe was prepared as described [8].
Briefly, an 848-bp CCR2 cDNA fragment (nucleotides
489–1336 of GenBank no. U77349) was cloned by PCR
using rat spleen cDNA. The resulting PCR product was
subcloned into a pGEM-T Easy vector and sequenced to
ensure identity for riboprobe use. The CCR2 template was
linearized with SacII to generate a probe of 950 bases by
using SP6 polymerase. Signals were visualized by using
NBT/BCIP reagents (Roche Diagnostics/Boehringer Man-
nheim, Indianapolis, IN) in the dark for 2–20 h depend-
ing upon the abundance of the RNA. Images were
captured using brightfield or differential interference con-
trast optics with a Nikon E600 fluorescent microscope
(NikonUSA, Melville, NY) fitted with a charge-coupled
device camera (Retiga EXi, Q-Imaging Corporation, Van-
couver, BC). CCR2 mRNA expression studies were used
for receptor localization because of the failure of immu-
nocytochemistry to detect neuronal CCR2 protein.
The RANTES plasmid was a gift from Dr. Richard M. Ran-
sohoff (Cleveland Clinic Foundation). The RANTES plas-
mid was sub-cloned into a pGEM vector. The plasmid
templates were linearized with restriction enzyme diges-
tion.Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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The CXCR4 and SDF-1 probes were generated as described
previously [21]. For the CXCR3 and CCR5 probes, we
used the CD1 mouse brain cDNA. The CXCR3 cDNA frag-
ment was amplified using the forward primer 5'-gag gtt agt
gaa cgt caa gtg-3' and the reverse primer 5'-tgg aga cca gca
gaa cag cta g-3'. The CCR5 fragment used the forward
primer 5'-tgg att atg gta tgt cag cac cc-3'and the reverse
primer 5'-tcg att atg gta tgt cag cac cc-3'. All PCR fragments
were subcloned into a pCR II-TOPO vector, and were ver-
ified by restriction analysis and automated DNA sequenc-
ing (Perkin Elmer, Boston MA)
The plasmid templates were linearized by restriction
enzyme digestion. Then transcription was labeled by dig-
oixigenin (Roche Applied Science, Indianapolis, IN).
Immunocytochemical labeling
Adult female Sprague-Dawley rats were deeply anesthe-
tized with isoflurane and transcardially perfused with
saline followed by 4% paraformaldehyde. Lumbar ganglia
associated with the sciatic nerve ipsilateral and contralat-
eral to focal nerve demyelination injury (n = 6) or sham
treatment (n = 6) were immediately removed following
behavior on POD 7 or 14 and postfixed for 4 hours. Addi-
tional lumbar DRGs were removed from naïve, behavio-
rally tested rats (n = 6). Lumbar DRGs were encoded at the
outset and processed in random order. Sagittal sections of
the DRG were serially cut at 14 μm onto SuperFrost micro-
scope slides (Fisher Scientific, Pittsburgh PA). At least 6
sections were obtained for immunocytological analysis
per DRG. Tissue was processed such that DRG sections on
each slide were at intervals of 80 um. Slides were incu-
bated with blocking buffer (3% BSA/3% horse serum/
0.4% Triton-X; Fisher Scientific, Pittsburgh PA) for 1 hour,
followed by overnight incubation with the rabbit polyclo-
nal antisera generated against MCP-1 (1:500; Chemicon,
Temecula, CA), IP-10 (1:1000, Abcam, Cambridge MA) or
CCR2 (1:500; Aviva Systems Biology, San Diego CA) at
room temperature. After primary incubation, secondary
antibodies (anti-rabbit conjugated to CY3, made in don-
key at 1:800; Jackson ImmunoResearch, West Grove, PA)
were used to visualize cells. Some experiments were aug-
mented with the addition of Griffoniasimplicifolia I-isolec-
tin B4 (IB4) conjugated with fluorescein (1 mg/1 ml;
Sigma, St. Louis MO). Slides were washed in PBS for 5 min
each (×3) and coverslipped with a PBS/glycerol solution.
All tissue sections were also stained with Hoechst 33258
nuclear marker (Invitrogen Corporation, Carlsbad CA).
Tissue sections were analyzed for the presence of IB4-bind-
ing neurons and either MCP-1, IP-10 or CCR2. Because a
stereological approach was not employed in this study,
quantification of the data may represent a biased estimate
of the actual numbers of immunopositive neurons. The
proportions of immunoreactive neurons were determined
from the total number of Hoescht-positive neuronal
nuclei present in a tissue section. The overall diameter and
brightness of the Hoescht-positive neuronal nuclei
allowed for a clear delineation between neurons and non-
neuronal cells in the DRG. At least 5000 neuronal profiles
from six animals (minimum of 625 cells per ganglia) were
quantified for each cell type in the single neuronal marker
study and for each combination of cellular markers.
Quantification of cell numbers, degree of colocalization
and cell diameters was determined using ImagePro Plus
(Media Cybernetics, Silver Spring, MD). As noted above,
individuals conducting cell quantification were blinded
to the treatment conditions. Data are represented as
means ± SEM%.
Preparation of acutely dissociated dorsal root ganglion 
neurons
The L4–L5 DRG were acutely dissociated using methods
described by Ma and LaMotte [22]. Briefly, L4 and L5 DRG
were removed from control or LPC-treated animals at var-
ious post-operative day timepoints. The DRGs were
treated with collagenase A and collagenase D in HBSS for
20 minutes (1 mg/ml; Roche Applied Science, Indianapo-
lis, IN), followed by treatment with papain (30 units/ml,
Worthington Biochemical, Lakewood, NJ) in HBSS con-
taining .5 mM EDTA and cysteine at 35°C. The cells were
then dissociated via mechanical trituration in culture
media containing 1 mg/ml bovine serum albumin and
trypsin inhibitor (1 mg/ml, Sigma, St. Louis MO). The cul-
ture media was Ham's F12 mixture, supplemented with
10% fetal bovine serum, penicillin and streptomycin (100
ug/ml and 100 U/ml) and N2 (Life Technologies). The
cells were then plated on coverslips coated with poly-L-
lysine and laminin (1 mg/ml) and incubated for 2 hours
before more culture media was added to the wells. The
cells were then allowed to sit undisturbed for 12–15 hours
to adhere at 37°C (with 5% CO2).
Intracellular Ca2+ imaging
The dissociated DRG cells were loaded with fura-2 AM (3
uM, Molecular Probes/Invitrogen Corporation, Carlsbad
CA) for 25 minutes at room temperature in a balanced salt
solution (BSS) [NaCl (140 mM), Hepes (10 mM), CaCl2
(2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (50
mM)]. The cells were rinsed with the BSS and mounted
onto a chamber that was placed onto the inverted micro-
scope and continuously perfused with BSS at a rate of 1
ml/min. Intracellular calcium was measured by digital
video microfluorometry with an intensified CCD camera
coupled to a microscope and MetaFluor software (Molec-
ular Devices Corporation, Downington, PA). Cells were
illuminated with a 150 W xenon arc lamp, and the excita-
tion wavelengths of the fura-2 (340/380 nm) were
selected by a filter changer. Chemokines were applied
directly into the coverslip bathing solution after the per-Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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fusion was stopped. If no response was seen within 1
minute, the chemokine was washed out. For all experi-
ments, MCP-1, SDF1, RANTES and IP10 were added to
the cells in random order, after which capsaicin, high K+
(50 K) and ATP were added. The chemokines used were
purchased from R & D Systems (Minneapolis, MN), and
all were used at a concentration of 100 nm to ensure max-
imal activation. They were reconstituted in 0.1%BSA/PBS,
and aliquots were stored at -20°C.
Statistical Analyses
Data is presented as the mean ± SEM, unless otherwise
noted. GB-Stat School Pack software (Dynamic Microsys-
tems, Inc. Silver Springs, MD) was used to statistically
evaluate all data. The significance difference was deter-
mined by two-way ANOVA with Bonferroni's post-hoc
test for animal behavior. The one way ANOVA with a
Dunnett's Multiple Comparison test was used to analyze
the differences between naïve, sham and experimental
groups. A difference of p < 0.05 was considered signifi-
cant.
Results
Mechanical stimuli elicit bilateral tactile hyperalgesia 
following LPC-induced sciatic nerve demyelination
To study changes in behavioral sensitivity following LPC-
induced nerve demyelination, we investigated alterations
in the paw withdrawal threshold (PWT) force of indenta-
tion (produced by von Frey filaments) necessary for elicit-
ing a flexion hindpaw withdrawal reflex. At POD1, the
PWT ipsilateral to the LPC-induced sciatic nerve demyeli-
nation was significantly reduced when compared to pre-
surgical PWTs (Fig. 1A). The force required to elicit a paw
withdrawal steadily declined until POD14, before gradu-
ally returning to near pre-surgical levels by POD35. These
PWTs met the pre-determined levels indicative of hyperal-
gesia (-20 mN force) between POD1 and POD28.
Changes in behavior were also observed in the hind paw
contralateral to the LPC-induced nerve injury (Fig. 1A).
These behavioral changes met the pre-determined PWT
levels indicative of hyperalgesia between POD3 and
POD28 (Fig. 1A). Vehicle-treated sham operated rodents
did not exhibit a PWT decrease that was significant at any
time point up to POD14. Animals given intramuscular
injections of LPC into the gastrocnemius muscle (10 ul,
1% LPC) did not develop cutaneous hyperalgesia (n = 3,
data not shown). These data indicate that a unilateral
LPC-induced nerve demyelination results in bilateral tac-
tile hyperalgesia.
Effect of unilateral focal nerve demyelination on thermal 
thresholds
In contrast to the effectiveness of LPC-induced focal nerve
demyelination in altering mechanical PWTs, focal nerve
Mean threshold force required for paw withdrawal to Von  Frey stimulation at 1, 3, 7, 14, 21, 28, 35 and 42 days follow- ing LPC-induced focal nerve demyelination Figure 1
Mean threshold force required for paw withdrawal to Von 
Frey stimulation at 1, 3, 7, 14, 21, 28, 35 and 42 days follow-
ing LPC-induced focal nerve demyelination. Each data point is 
the mean threshold (± SE) force on the hindpaw ipsilateral 
(black circle) or contralateral (white circle) to the focal nerve 
injury site eliciting a withdrawal response (n = 10). Reduced 
behavioral thresholds for the hindpaw ipsilateral to the nerve 
lesion were significantly different from pre-operative baseline 
on postoperative days 1–28. The threshold force for the 
hindpaw contralateral to the nerve lesion did not reach sig-
nificance until postoperative day 3, and significant differences 
were observed until postoperative day 28. The time course 
of sham injury (n = 6) is also represented but did not differ 
from the uninjured animals. Analysis was performed using 
two-way ANOVA followed by the Bonferroni post-hoc pair-
wise comparisons (*p < 0.01).B) LPC-induced focal nerve 
demyelination did not produce changes in thermal responses 
as assessed by the Hargreaves test. Each bar is the mean 
withdrawal latency (± SE) of the hindpaw ipsilateral (white 
bar) or contralateral (black bar) to the focal nerve demyeli-
nation injury at postoperative day 7 and 14 (n = 10).
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demyelination had little if any effect on thermal respon-
sivity from POD0 to POD14 (Fig. 1B).
CCR2, CXCR4, CXCR3 and CCR5 upregulation in L4–L5 
DRG after unilateral LPC-induced nerve demyelination
We previously reported upregulation of CCR2 chemokine
receptor signaling in association with chronic compres-
sion of the DRG [8]. We therefore examined the state of
CCR2 expression in association with LPC-induced demy-
elination. L4L5  DRGs removed from naïve (data not
shown) and vehicle-treated rats at POD7 did not express
CCR2 mRNA (Fig. 2A) or CCR2 immunoreactivity (Fig.
2B). Small and medium diameter L4L5 neurons ipsilateral
to the focal nerve lesion exhibited low levels of both
CCR2 mRNA transcripts at POD7 (Fig. 2C) and CCR2
immunoreactivity (Fig. 2D). By POD14, many sensory
neurons of all diameters exhibited CCR2 mRNA in L4L5
DRGs both ipsilateral and contralateral to LPC-induced
injury (Figs. 2E, 3). Immunoreactivity for neuronal CCR2
at POD14 (Fig. 2F) was also increased relative to POD7.
Neuronal binding of the plant isolectin, Griffoniasimplici-
folia B4 (IB4) in the rat DRG distinguishes a population of
C-fiber nociceptors [23,24]. We double-labeled the sec-
tions stained for CCR2 protein with IB4. Many IB4-bind-
ing neurons were present in lumbar DRG of naïve, sham-
operated rats and those subjected to LPC-induced focal
nerve demyelination (Fig. 2B, D, F). These neurons dis-
played strong labeling of the plasma membrane, as well as
perinuclear staining that in all likelihood represents the
Golgi apparatus [25]. Quantitative analysis of neurons
positive for CCR2 revealed that 33.35 ± 2.16% of sensory
neurons ipsilateral and 35.87 ± 3.36% contralateral to the
nerve lesion were positive for the chemokine receptor.
Relatively few (<6%) CCR2-positive neurons were colo-
calized with IB4-binding neurons ipsilateral (Fig. 2F and
Fig. 3) or contralateral to the nerve injury at POD 14 (Fig.
3). CCR2 mRNA was no longer detected in lumbar DRGs
taken from injured animals on POD35 (data not shown).
Activation of numerous chemokine receptors in addition
to CCR2 might potentially be involved in the production
of sensory neuron hyperexcitability and pain [3,4,26]. The
chemokine SDF-1/CXCL12 and its receptor CXCR4 are
constitutively expressed by peripheral nerves [3,27-29]
and chemokines that activate CCR5 and CXCR3 receptors,
such as RANTES and IP-10, are synthesized in association
with neuroinflammatory responses [16,30]. To investi-
gate whether chemokine receptors, in addition to CCR2,
are upregulated following focal nerve demyelination, in
situ hybridization studies were performed on injured rat
DRG tissue sections.
Basal expression of CXCR4 mRNA was predominantly
detected in non-neuronal cells of the lumbar DRG derived
from naïve animals (data not shown). This level of non-
neuronal expression did not change appreciably follow-
ing vehicle treatment (Fig. 4A and 4C) or focal nerve
demyelination at POD14 (Fig. 4B). Despite little change
in non-neuronal cells, there was an increase in the
number of neurons expressing CXCR4 mRNA transcripts
by POD14 in the lumbar DRG ipsilateral to the nerve
lesion (Fig. 4D). This pattern of staining was also
observed in DRG contralateral to the nerve injury (data
not shown). DRGs taken from injured animals on POD35
exhibited CXCR4 mRNA staining that was similar to that
seen in naïve and vehicle-treated animals (data not
shown).
Next we used in situ hybridization to examine the expres-
sion of the chemokine receptors CXCR3 and CCR5 in the
DRG associated with the LPC-induced focal demyelina-
tion. These are the receptors for the chemokines IP-10 and
RANTES (among other chemokines) respectively. Many
sensory neurons were positive for CXCR3 mRNA in tissues
taken from both naïve (data not shown) and sham-treated
rodents at POD14 (Fig. 5A). The pattern of neuronal
expression of CXCR3 mRNA at POD14 following focal
nerve demyelination did not change relative to naïve or
sham-treated tissue, but the nerve injury did increase the
intensity of CXCR3 mRNA expression in the DRG ipsilat-
eral to the injury (Fig. 5C), as well as in the contralateral
DRG (data not shown).
Unlike CXCR3 expression, lumbar DRG in naïve (data not
shown) and sham-treated rats at POD14 (Fig. 5B) were
devoid of CCR5 mRNA transcripts. As with CCR2 expres-
sion in sensory neurons, CCR5 mRNA transcript levels
were strongly increased in many sensory neurons ipsilat-
eral and contralateral to the nerve injury at POD14 (Fig.
5D). Lumbar DRGs derived from injured animals on
POD35 showed no CCR5 mRNA staining (data not
shown).
Chemokine expression in response to LPC-induced 
demyelination of the sciatic nerve
As the data discussed above indicates strong expression of
several chemokine receptors by sensory neurons follow-
ing LPC-induced demyelination injury, we sought to
determine whether sensory neurons would also exhibit
changes in the expression of chemokines that are possible
ligands for these receptors under the same circumstances.
Using immunocyctochemistry, we examined both the
nerve lesion site and lumbar DRG associated with the
injured nerve for MCP-1/CCL2 protein expression.
Despite the multitude of ED-1-immunopositive macro-
phages in the injured sciatic nerve, MCP-1/CCL2-immu-
noreactive cells were absent from the nerve lesion site on
POD1, 3, 7, 14 (data not shown), lumbar DRG removed
from naïve rats (data not shown) and lumbar DRG from
vehicle-treated rats at POD7 (Fig. 6A). In sharp contrast,Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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Expression of CCR2 mRNA and protein immunoreactivity in rat lumbar DRG ipsilateral to focal nerve demyelination Figure 2
Expression of CCR2 mRNA and protein immunoreactivity in rat lumbar DRG ipsilateral to focal nerve demyelination. A) Lum-
bar DRG removed from vehicle-treated animals at POD7 did not exhibit CCR2 mRNA expression (n = 5). B) Many lumbar 
DRG neurons in vehicle-treated rats sensory neurons were positive for isolectin IB4, a neuronal phenotype that distinguishes 
some C-fiber nociceptors (green cells). There was no evidence of CCR2 protein expression in sham animals (n = 5). C) Lum-
bar DRG neurons from nerve-injured rats on POD7 exhibited CCR2 mRNA transcripts in some small and medium diameter 
neurons (black arrows). Open black arrowhead indicates a neuron without CCR2 mRNA transcripts (n = 4). D) Lumbar DRG 
neurons from a rat subjected to focal nerve demyelination exhibited few CCR2 immunopositive (white arrows) sensory neu-
rons (n = 4). E) Many lumbar DRG neurons on POD14 exhibited CCR2 mRNA transcripts (black arrows). Open arrowhead 
indicates non-labeled neuron. F) CCR2 immunoreactivity was present in an increased number of neurons at POD14 (white 
arrows; n = 5). Scale bar is; 30 μm (A, C), 50 μm (B, D, F), and 100 μm (E).
 Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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numerous MCP-1 immunopositive neurons were present
in associated lumbar ganglia of the LPC-treated rats by
POD7 (Fig. 6B). The diameter of MCP-1 immunoreactive
neurons in the LPC-treated animals averaged 26.49 ± 0.47
μm (n = 6). Interestingly, no MCP-1 protein immunoreac-
tivity was detectable in injured DRG non-neuronal cells at
any time point examined.
Once again, we co-stained DRG sections with IB4, a
marker for C-fiber nociceptors. Many IB4-binding neurons
were present in lumbar DRG of naïve, sham-operated and
nerve-injured rats at POD7 and POD 14 (Fig. 6C) and Fig.
3, respectively). The average number of IB4  neurons
present in the lumbar DRG was 47.87 ± 1.44% (n = 6 per
condition) and did not significantly differ across treat-
ment groups (sham and injured at POD14) (Fig. 3; p >
0.1). A series of MCP-1 immunopositive/IB4-binding
colocalization experiments demonstrated that a signifi-
cant portion of the MCP-1 positive neurons co-localized
with IB4 at POD 7 and POD 14 (Fig. 6B, D; Fig. 3). More
specifically, just over half of the MCP-1 immunoreactive
neurons present at POD14 in DRG ipsilateral to nerve
injury were also positive for IB4 (Fig. 3; 20.12 ± 0.75%; n
= 6).
In a previous study, it was shown that in a rodent model
of spinal stenosis, chronic compression of the DRG, there
was increased MCP-1 expression and increased excitabil-
ity of sensory neurons in injured and adjacent uninjured
DRG [8]. Therefore, we wished to see whether MCP-1
activity was altered in the L4/L5 DRG contralateral to the
nerve injury. Increased numbers of MCP-1-immunoreac-
tive cells were present in ganglia contralateral to nerve
injury (Fig. 3; 34.27 ± 1.17%; n = 6) and 13.32 ± 0.57%
(n = 6) exhibited IB4 colocalization. Relatively few neu-
rons were positive for MCP-1 in ganglia ipsi- or contralat-
Percentage of MCP-1, CCR2 and IP-10 immunoreactive neurons with IB4-positive neuronal profiles on POD 14 Figure 3
Percentage of MCP-1, CCR2 and IP-10 immunoreactive neurons with IB4-positive neuronal profiles on POD 14. MCP-1 
expression was increased by LPC-induced nerve injury within the IB4-labeled neuronal group in both the DRG ipsilateral and 
contralateral to the nerve injury. Sham-injury treatment did not produce significant changes in the extent of MCP-1/IB4 colocal-
ization. CCR2 expression was increased by LPC-induced nerve injury within IB4-labeled neuronal group in both the DRG ipsi-
lateral and contralateral to the nerve injury. Like, MCP-1, sham-injury treatment did not produce significant changes in CCR2/
IB4 colocalization in either DRG ipsi- or contralateral to the sham injury. IP-10 expression was increased by LPC-induced 
nerve injury within IB4-labelled neuronal group in both the DRG ipsilateral and contralateral to the nerve injury, while sham-
injury treatment did not produce significant changes in IP-10/IB4 colocalization. Comparisons of immunoreactive cell percent-
ages were made between LPC-treatment and sham-treated animals. Data represent means ± SE. Analysis was performed using 
two-way ANOVA followed by the Bonferroni post-hoc pair-wise comparisons (*p < 0.01).
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eral to the injury site in sham-treated animals (Fig. 3;
<5%) and IB4 colocalization was rare (Fig. 3).
As noted above, nearly every neuron in the DRG ipsilat-
eral to the nerve injury upregulated CCR5. We used in situ
hybridization to study the levels of RANTES expression,
one known ligand for CCR5, in the DRG ipsilateral and
contralateral to the nerve injury. RANTES expression was
absent in the L4/L5 DRG in vehicle treated rats (Fig 7A).
We found that after nerve injury, RANTES expression was
strongly upregulated in DRG neurons ipsilateral and con-
tralateral to the nerve injury, when compared to sham
control tissue. Like CCR5, RANTES was expressed in
small, medium and large sensory neurons (Fig 7B, C).
SDF-1 is the unique ligand for the CXCR4 receptor
[31,32]. It has been reported that Schwann cells in the
peripheral nerve express SDF-1 and that its expression
increases moderately after nerve injury [3,29,33]. Using in
situ hybridization we examined lumbar DRG associated
with the injured sciatic nerve for SDF-1 expression at
POD14. Many lumbar DRG non-neuronal cells present in
both the naïve (data not shown) and vehicle-treated rats
were positive for SDF-1 mRNA transcripts (Additional file
2A, C). Neither the pattern nor the expression levels of
SDF-1 mRNA transcripts changed following focal nerve
demyelination at POD14 (Additional file 2B, D).
IP-10 is one of three ligands that bind to the CXCR3 recep-
tor [34-36]. Little is known, however, concerning a role
for IP-10 in sensory neuron function. We demonstrated
Expression of CXCR4 mRNA in rat lumbar DRG ipsilateral to focal nerve demyelination Figure 4
Expression of CXCR4 mRNA in rat lumbar DRG ipsilateral to focal nerve demyelination. Low (A) and high power (C) phot-
omicrographs of CXCR4 mRNA transcripts present in lumbar DRG removed from vehicle-treated rodents at POD14 (n = 3). 
Many non-neuronal cells strongly expressed CXCR4. (C) Some presumptive neurons expressed low levels of CXCR4 mRNA 
(white arrow). Low (B) and high power (D) photomicrographs of CXCR4 mRNA transcripts present in lumbar DRGs derived 
from injured rats at POD14 (n = 4). The expression level and number of non-neuronal cells exhibiting CXCR4 mRNA tran-
scripts in the lumbar DRG did not change following focal nerve demyelination. However, many neurons upregulated CXCR4 
mRNA expression (D; white arrows indicate neurons with low levels of mRNA transcripts; white arrowhead points to a neu-
ron lacking CXCR4 mRNA expression). (Scale bar is 1 mm (A and B); 40 μm (C and D).Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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that the sensory neurons in both vehicle-treated and
injured lumbar DRGs exhibited appreciable levels of
CXCR3 expression (Fig. 5A, C). Similarly, lumbar DRG
from both naïve (data not shown) and vehicle-treated
rodents displayed constitutive IP-10 immunoreactivity
(12.04 ± 1.2%, at least 400 cells/DRG from each of 6 vehi-
cle-treated animals) (Fig. 3, Fig. 8A), both ipsi- and con-
tralateral to the site of nerve injury. The mean diameter of
IP-10-immunopositive neurons in the vehicle-treated rat
was 47.53 ± 1.7 μm. Seven days after LPC-induced focal
nerve demyelination, the number of IP-10-immunoposi-
tive neurons in injured DRG had increased over two-fold
to 30.41 ± 2.9% (n = 6) (Fig. 3, Fig. 8B). The average cell
diameter of IP-10 immunoreactive neurons on POD7 was
significantly reduced to 34.49 ± 0.98 μm. By POD14, the
number of IP-10 immunoreactive sensory neurons had
increased over three-fold (when compared to the vehicle-
treated rat lumbar DRGs) to 36.8 ± 4.9% of the total neu-
ronal population (Fig. 3, Fig. 8C), and the average neuro-
nal diameter was further reduced to 29.74 ± 1.1 μm (n =
6).
A reduction in the average diameter of IP-10-immunopo-
sitive neurons concurrent with a three-fold increase in the
number of neurons implies upregulated expression of IP-
10 occurred in cells normally negative for the chemokine.
Similar to previous findings in subpopulations of cells
positive for the neurotrophin brain-derived neurotrophic
Expression of CXCR3 and CCR5 mRNA in rat lumbar DRG following focal nerve demyelination Figure 5
Expression of CXCR3 and CCR5 mRNA in rat lumbar DRG following focal nerve demyelination. (A) Many sensory neurons in 
the lumbar DRG removed from vehicle-treated rats exhibited CXCR3 mRNA transcripts at POD14 (n = 3). (B) CCR5 mRNA 
expression was absent from the lumbar DRG of vehicle-treated rats at POD14 (n = 3). (C) CXCR3 mRNA expression pat-
terns in sensory neurons subjected to focal nerve demyelination did not differ from vehicle-treated rodents at POD14 (n = 4), 
but there was an increase in the intensity of CXCR3 mRNA expression. (D) Many neurons in the injured rat lumbar DRG 
expressed CCR5 transcripts at POD14 (n = 4). Scale bar is 250 μm (A and C); 100 μm (B and D).Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
Page 11 of 20
(page number not for citation purposes)
factor (BDNF) by Obata and colleagues [37], this change
in neuronal phenotype may be indicative of pathophysio-
logical changes in primary afferent neurons following
focal nerve demyelination. To determine the degree to
which small, presumably nociceptive IB4-binding neu-
rons, also displayed IP-10 immunoreactivity following
LPC-induced nerve demyelination, we performed a series
of colocalization experiments (Fig. 8D–I). Our analysis
revealed that generally speaking, IP-10 immunoreactive
neurons did not co-localize with IB4-binding neurons in
vehicle-treated lumbar DRG (Fig. 3, Fig. 8D, G). On
POD7, 9.39 ± 1.64% of the total neurons exhibited both
IP-10 immunoreactivity and IB4-binding (n = 6) (Fig. 3,
Fig. 8E, H). However, a two-fold increase in the number
of neurons positive for both IP-10-immunoreactivity and
IB4-binding (19.08 ± 2.31%; n = 6) was evident at POD14
(p < 0.01) (Fig. 3, Fig. 8F, I).
Chemokines increase [Ca2+]i in DRG cells subjected to 
LPC-induced nerve demyelination
Activation of chemokine receptors expressed by primary
sensory neurons results in excitation and in the increase in
the intracellular Ca2+concentration [4]. To compliment
the anatomical observations of upregulated chemokine
Colocalization of MCP-1 immunoreactivity (ir) and isolectin B4(IB4)-binding in the lumbar DRG ipsilateral to LPC-induced  demyelination injury at POD7 Figure 6
Colocalization of MCP-1 immunoreactivity (ir) and isolectin B4(IB4)-binding in the lumbar DRG ipsilateral to LPC-induced 
demyelination injury at POD7. IB4-binding in rat DRG neurons distinguishes C-fiber nociceptors. (A) Naïve rat lumbar DRG 
were completely negative for MCP-1ir. (B) Lumbar DRG ipsilateral to LPC-induced sciatic nerve injury exhibited numerous 
small diameter neurons that are MCP-1 positive at POD7 (red arrows). (C) Numerous small IB4-binding presumptive nocicep-
tors are present in the same DRG tissue section (green arrows). (D) Merging panels B and C demonstrates the extent of colo-
calization present in lumbar DRG tissue section (yellow arrows). Note not all MCP-1ir neurons were positive for IB4 at POD7 
(red arrow). Scale bar is 100 μm (A, B, C and D).Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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receptor expression, we used fura-2 imaging of chemok-
ine-induced increases in [Ca2+]i in acutely isolated rat
DRG neurons as a measure of functional chemokine
receptor expression. We acutely isolated the DRG cells
from both the ipsilateral and contralateral sides of nerve
injured animals and sham controls. For all experiments,
the chemokines MCP-1, SDF-1, RANTES and IP-10 were
added in random order to the cells, after which capsaicin,
high K+(50 mM) and ATP were added to assess the cells'
identity and viability, respectively. A response to high K+
stimulation indicates the presence of voltage dependent
Ca2+ channels, which is indicative of neurons. Addition-
ally, a positive response to capsaicin as well as high K+
indicates the cell is a nociceptor expressing the TRPV1
channel. A response to ATP, which activates purinergic
receptors, without one to High K+ and/or capsaicin, indi-
cates a non neuronal cell, presumably a type of glial cell
such as a satellite glial cell or Schwann cell. The concentra-
tions of chemokines used in these experiments were all
supramaximal to ensure activation of any expressed recep-
tors.
It was evident that an increased number of cells
responded to MCP-1 application from POD 14–28 in the
DRG cells ipsilateral to the nerve injury (Fig. 9B and 9C),
(Table 1), when compared to vehicle-treated control ani-
mals (Fig 9A). The number of cells responding went from
5.8% to 31.7% by POD 28. The majority of these cells
were characterized as neurons based on their positive
responses to capsaicin and/or high K+ (Table 2). Many
cells also exhibited increases in [Ca2+]i in response to the
other chemokines tested (i.e. SDF1, RANTES and IP-10)
and the frequency of these responses was always greatest
by POD 28 in the nerve injured animals. Chemokine-
induced changes in dissociated DRG were not limited to
sensory neurons, but also included occasional non-neuro-
nal cells (Table 2). It was also noted that at POD 14, most
cells responded to only one chemokine. However, at POD
28, when upregulated chemokine signaling was at its
greatest, most cells responded to multiple chemokines,
indicating that single neurons expressed multiple chem-
okine receptors. In the DRG contralateral to the nerve
injury, there was an upward trend in chemokine signaling
at POD 14–28 (Table 1), but this did not reach signifi-
cance. By POD 35, dissociated DRG cell responses to
chemokines had returned to baseline levels (Fig. 9D,
Table 1). Thus, the fura-2 imaging generally confirmed the
observed upregulated expression and function of chemok-
ine signaling in DRG cells subjected to a peripheral nerve
demyelination.
CCR2 receptor antagonist attenuates bilateral focal nerve 
demyelination induced tactile hyperalgesia
Using LPC nerve-injured animals, we tested the effect of a
single i.p injection of a CCR2 receptor antagonist (CCR2
RA-[R]) or its inactive enantiomer (CCR2 RA-[S]) on
nociceptive behavior at POD14 and POD28 (10 mg/kg).
Neither vehicle nor CCR2 RA-[S] administration at day 14
or day 28 had an effect on the bilateral mechanical PWT
when tested 1 hour later (Fig. 10). In contrast, bilateral
increases in PWT were observed one hour after adminis-
tration of CCR2 RA-[R]. These PWTs did not differ from
pre-operative basal threshold levels (Fig. 10). The effects
of CCR2 RA-[R] were stereospecific as administration of
an equal dose of the inactive stereoisomer did not inhibit
pain behavior. All PWTs returned to pre-drug administra-
tion levels within 24 hours (data not shown).
Discussion
Previous work carried out in our own and other laborato-
ries has indicated that chemokine signaling may contrib-
ute to the genesis and maintenance of neuropathic pain
Expression of RANTES mRNA in rat lumbar DRG following focal nerve demyelination Figure 7
Expression of RANTES mRNA in rat lumbar DRG following focal nerve demyelination. (A) RANTES mRNA expression was 
absent from the lumbar DRG of vehicle-treated rats at POD14 (n = 3). (B) Many sensory neurons in the DRG ipsilateral to the 
nerve injury at POD 14 were positive for RANTES mRNA (C) Numerous sensory neurons in the DRG contralateral to the 
nerve injury displayed expression of RANTES mRNA, albeit at a lower level when compared with the DRG ipsilateral to the 
nerve injury. Scale bar is 250 μm (A and C); 100 μm (B and D).Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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[11,17,18]. Thus, the present studies were designed to
investigate a potential association between focal nerve
demyelination, neuropathic pain behavior and chemok-
ine signaling in DRG neurons. Based on our previous
studies, we hypothesized that the focal demyelination of
the sciatic nerve, a known rodent model of neuropathic
pain [12], would result in upregulated chemokine expres-
sion and chemokine receptor signaling in DRG neurons.
Indeed, we observed the predicted increases for several
chemokines and their receptors. Importantly, as the PWT
decreased over 14 days post-injury, chemokines, chemok-
ine receptors and chemokine/receptor signaling increased
significantly. This occurred not only in the DRG directly
associated with the injured nerve, but also to a lesser
degree, in the DRG directly contralateral to the nerve
injury. Bilateral nociceptive behavior was apparent
between days 3–28 and could be stereospecifically atten-
uated with a CCR2 receptor antagonist on days 14 and 28.
Moreover, five weeks following injury, both the neuro-
pathic pain behavior and the incidence of chemokine sig-
naling were greatly diminished. Together with the known
cellular effects produced by chemokines on sensory neu-
Colocalization of IP-10 immunoreactivity (-ir) and isolectin B4 (IB4)-binding neurons in the lumbar DRG of naïve rat and rats  subjected to LPC-induced nerve injury Figure 8
Colocalization of IP-10 immunoreactivity (-ir) and isolectin B4 (IB4)-binding neurons in the lumbar DRG of naïve rat and rats 
subjected to LPC-induced nerve injury. IB4-binding in rat DRG neurons distinguishes a population of C-fiber nociceptors. A) 
The majority of IP-10-ir cells were limited to medium diameter neurons in the lumbar DRG from vehicle-treated rats (red 
arrows). D) IB4-binding small diameter presumptive nociceptors (green arrows) did not colocalize with IP-10-ir lumbar DRG 
neurons from vehicle-treated rodents at POD7 (G, merged images). B) Lumbar DRG ipsilateral to focal nerve demyelination 
exhibited numerous medium and small diameter IP-10-ir neurons at POD7. Limited numbers of neurons were positive for both 
IP-10-ir (B, red arrows) and IB4-binding (E, green arrows) on POD7 (H, merged images). C) Many IP-10-ir neurons (red 
arrows) colocalized with IB4-binding neurons (F, green arrows) at POD14 (I, merged images). Yellow arrows indicate colocal-
ized cells. Scale bar is 100 μm.Molecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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rons [3,7], these results suggest that the changes in sensory
neuron chemokine/receptor signaling may be central to
the maintenance phase of neuropathic pain behavior in
particular.
The results of our previous studies, together with the
present results on LPC-associated neuropathy, point to a
significant role for chemokine signaling expressed directly
by peripheral nerves. For example, we have previously
demonstrated that activation of chemokine receptors
expressed by cultured or acutely isolated DRG neurons
produces increased (Ca2+)i, or neural excitation [4,38].
Indeed, following upregulation of CCR2 by sensory neu-
rons in whole DRG derived from animals exhibiting neu-
ropathic pain, application of MCP-1 produces powerful
excitation [8]. The mechanism underlying this response
probably involves activation of phospholipase C-induced
degradation of PIP2, production and concomitant trans-
activation of TRPV1 and/or TRPA1 together with inhibi-
tion of K+ conductance [9,10].
The experiments reported here suggest a model in which
focal nerve demyelination produces a concomitant upreg-
ulation of several chemokines and their receptors in the
cell bodies of sensory neurons in the DRG. We have
observed that chemokines expressed by DRG neurons,
including MCP1, IP10 and SDF1, can be packaged into
secretory vesicles and released upon depolarization [9].
Presumably, chemokines released in this fashion may
influence neural cells in the local vicinity eliciting excita-
tion as described above. Such activation would produce
further chemokine release and excitation driving the over-
all excitability of the chemokine sensitive neurons to new
levels. The resulting neuronal behavior may explain cer-
tain aspects of pathologically maintained neuronal states
of depolarization or electrical hyperexcitability of periph-
eral sensory neurons [39-41]. In addition to the chronic
maintenance of sensory neuron hyperexcitability, release
of chemokines such as MCP-1 and fracktalkine from cen-
tral axon terminals in the spinal cord may initiate micro-
glial-mediated neuropathic pain states [7,11,42-44].
However, it is important to note that pharmacological
therapies which inhibit microglial activation and effec-
tively attenuate the development of hyperalgesia and allo-
dynia have no effects on preexisting nociceptive pain
behavior [45].
As we have demonstrated, the exact pattern of changes in
chemokine signaling observed following focal nerve
demyelination depends on the particular chemokine
receptor and ligand examined. There are over 50 known
chemokines and 20 chemokine receptors [32], and it is
obviously not feasible to study all of these simultane-
ously. However, the receptors studied in the present
experiments represent obvious candidates for a role in
peripheral neuropathy. Chemokines that signal via the
CCR2, CCR5, CXCR3 and CXCR4 receptors have previ-
ously been shown to influence the behavior of sensory
neurons [3,4,6,8,11,17]. Furthermore, many of these
receptors can be upregulated in leukocytes by mecha-
nisms suggesting that regulation of their expression may
often be coordinated through the same transcriptional
control mechanisms [46].
Table 2: At 28 days, the majority of cells responded to capsaicin 
or high K+, indicating that most of the chemokine responsive 
cells were neurons.
Capsaicin/High K+/ATP positive (TRPV1 
expressing nociceptor)
39.1%
High K+/ATP positive only (Non TRPV1-
expressing neuron)
39.1%
ATP positive only (Non-neuronal cell) 21.7%
Table 1: Table illustrates the chemokine response profile of acutely dissociated DRG cells from rats with and without peripheral nerve 
injury (n = 5/group). The cells were imaged while the various chemokines were added to the bathing solution. A rise in (Ca)i after 
chemokine application was indicative of the expression of a functional chemokine receptor. After chemokine application, capsaicin, 
high K+ and ATP were used to characterize the identity of the cells (see text). Note the upregulation of chemokine signaling at 14 and 
28 days after peripheral nerve demyelination in isolated DRG cells ipsilateral to the nerve injury. There was also an upward trend in 
chemokine signaling in the cells isolated from the DRG contralateral to nerve injury at POD 14–28. By POD 35, chemokine 
responsiveness returned to baseline levels.
Control POD 14 POD 28 POD 35
Chemokine Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral
MCP-1 5.8% 7.9% 11.6% 2.5% 31.7% ** 15.1% 2.4% 0.0%
SDF1 5.8% 7.0% 2.3% 5.0% 25% ** 8.2% 7.3% 6.6%
RANTES 5.8% 7.0% 23.2% ** 2.5% 8.3% 13.6% 9.7% 3.3%
IP-10 9.6% 8.8% 0.0% 20.0% 21.1%* 8.2% 7.3% 6.6%
*p < 0.01
** p < 0.05
n = 5/age groupMolecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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The four chemokines/chemokine receptors that we stud-
ied all displayed different patterns of expression in
response to focal nerve demyelination, suggesting differ-
ent roles in the genesis of pain or other functions in the
DRG. The upregulation of MCP-1 and the CCR2 chemok-
ine receptor observed in association with focal nerve
demyelination is similar to the pattern we previously
observed using a spinal stenosis model of neuropathic
Chemokines increased [Ca2+]i levels in acutely isolated rat DRG cells following focal demyelination injury Figure 9
Chemokines increased [Ca2+]i levels in acutely isolated rat DRG cells following focal demyelination injury. The figure shows 
examples of responses of cells acutely isolated from rat DRGs ipsilateral to the nerve injury at various days after a focal demy-
elination injury. Under normal conditions, cells rarely respond to any chemokine but did respond to other stimuli such as high 
K or ATP (A). However, there was an increased responsiveness of the cells, the majority of which could be characterized as 
neurons, between post-operative days 14–28 (B and C, respectively). The frequency of the responses to chemokines 
returned to approximately the same level as control animals by post-operative day 35 (D). For all experiments, MCP-1 (M), IP-
10 (I), RANTES (R), SDF1 (S) were applied at a concentration of 100 nM. Capsaicin (C), high K (K) and ATP (A) were applied 
at concentrations of 100 nM, 50 mM and 100 uM, respectively.
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pain [8]. Indeed, CCR2 receptor deficient mice are resist-
ant to the induction of some sensory neuropathies, high-
lighting the potential importance of this chemokine
signaling system [11]. In the current experiments, we uti-
lized a Ca2+ imaging paradigm in lieu of electrophysiolog-
ical recording, as chemokine-induced increased neuronal
excitability would be expected to be correlated with a
chemokine induced increase in (Ca2+)I. The observed
increase and subsequent decrease in MCP-1-induced
Ca2+responsiveness in acutely isolated DRG neurons over
time generally correlated with the anatomical observa-
tions of receptor expression, and both effects returned to
baseline by POD 35. Importantly, the ability of the CCR2
receptor antagonist to attenuate bilateral nociceptive
behavior at both 14 and 28 days after nerve injury strongly
suggests an integral role for MCP-1/CCR2 signaling in
maintaining this phase of pain hypersensitivity.
Although the CCR2 antagonist was effective in blocking
pain hypersensitivity, more than one chemokine or chem-
okine receptor was upregulated in this neuropathic pain
model. The particular effectiveness of CCR2 block could
be due to the fact that upregulation of chemokines can be
bilaterally expressed in different populations of sensory
neurons following nerve injury, as is this case of chole-
cystokinin vasoactive inhibitory peptide and neuropep-
tide Y [43,47]. In our experiments over 50% of the cells
that upregulated MCP-1 also expressed IB-4, which is a
marker for C-fiber nociceptors that are responsible for
transmitting pain information. This differs from the case
of IP-10, where a majority of the neurons upregulating
this chemokine did not co-localize with IB-4. As such, it is
possible that the population of neurons that upregulates
CCR2 signaling is particularly linked to the production of
neuronal hyperexcitability. It is also likely that the CCR2R
antagonist may impact non-neuronal cells within the
CNS, such as microglial cells, which are known to express
CCR2 in the spinal cord and contribute to the develop-
ment of chronic pain states [11,48,49].
The precise location of action of the CCR2 antagonist is
not known. However, it has been shown that the blood
nerve barrier is less restrictive than the blood brain barrier
[50], with the cell body rich area of the DRG being vulner-
able to extravascular leakage. Given these studies, it is
likely that the CCR2 R antagonist reached the cell bodies
of the DRG. As activation of CCR2 receptors in the DRG is
probably of considerable importance in the production of
pain behavior it is likely that block of these receptors con-
tributes to the antinociceptive effects of the CCR2 antago-
nist.
In the face of the effectiveness of CCR2 receptor block
either pharmacologically (Fig 9) or genetically [11], the
function of other types of upregulated chemokine signal-
ing to chronic pain behavior is not immediately obvious.
Like CCR2, the CCR5 receptor function and its ligand,
RANTES, were also strongly upregulated in DRG neurons
in response to focal demyelination. It has previously been
shown that RANTES may be important in other chronic
pain situations [51]. Our findings in this sciatic nerve
injury model differ from a report by Taskinen and Royotta
[16] which demonstrated bilateral upregulation of non-
neuronal RANTES for up to four weeks following sciatic
nerve transection in the rat. The apparent differences may
be due to the nature of the nerve injuries. Alternatively,
CCR5 may also be activated by a number of other chem-
okine ligands which we did not measure [52]. Chemokine
interactions with CCR5 may also depress the analgesic
action of endogenous opioids and/or sensitize TRPV1
[10,53,54] thereby generally promoting hyperalgesia.
The signaling pattern of IP-10 and CXCR3 receptors in the
DRG differs in some respects as there is appreciable basal
neuronal expression of both CXCR3 receptors and IP-10.
In spite of this, few Ca2+  neuronal responses were
CCR2 receptor antagonist (CCR2 RA-[R]) administration  reversed existing nociceptive behavior Figure 10
CCR2 receptor antagonist (CCR2 RA-[R]) administration 
reversed existing nociceptive behavior. Animals were sub-
jected to a nerve demyelination injury on day 0 and nocicep-
tive behavior was assessed for 28 days. On days 14 and 28 
post-surgery, animals received 5 mg/kg CCR2 RA-[R] or 5 
mg/kg of its inactive enantiomer, (CCR2 RA-[S], or saline by 
intraperitoneal injection, and behavioral responses were 
tested 1 h later. Administration of the CCR2 RA-[R] to focal 
nerve demyelination injured rats resulted in a significant bilat-
eral increase of mN force required to elicit a paw withdrawal 
compared with vehicle-treated controls and animals sub-
jected to CCR2 RA-[S]. Nociceptive behavior in vehicle-
treated controls and animals subjected to CCR2 RA-[S] dif-
fered significantly from day 0 pre-injury baseline responses 
(*p < 0.01). Data represent means ± SE.
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observed in the naïve or sham animals, perhaps because
of desensitization resulting from ongoing receptor activa-
tion induced by constitutive expression of IP-10. Neuro-
nal expression of IP-10/CXCR3 under basal conditions
may have a specific role to play that is analogous to the
expression and release of fractalkine by neurons [42,55].
Following strong neuronal excitation in the peripheral
nervous system (i.e. trauma or disease), IP-10 may be
released within the DRG and/or from central terminals in
the spinal cord dorsal horn resulting in both local and dis-
tant glial activation [26,56,57].
Focal nerve demyelination changes in SDF-1 signaling via
the CXCR4 receptor show still another pattern. In this
case, the chemokine receptor is not generally expressed in
neurons, but in satellite glia and Schwann cells. Upregu-
lated CXCR4 expression, however, is primarily restricted
to neurons making them a potential target for the release
of SDF-1 from glia. It is interesting to note that a role for
Schwann cell release of SDF-1 and for neuronally-
expressed CXCR4 receptors has also been suggested in
recently proposed models of HIV-1 and NRTI related neu-
ropathies [14,51].
It is clear that focal nerve demyelination injury-induced
behavioral changes are correlated with widespread
changes in the neuronal expression of chemokine/recep-
tors and that the pattern of expression of each chemokine
and its receptor is unique, suggesting that the influence of
chemokine signaling on rodent nociceptive behavior may
be complex. It should also be noted that the upregulated
expression of different chemokines and receptors that we
have observed may occur as part of a cytokine "cascade",
where the expression of one chemokine or its receptor is
dependent on previous events. If that is the case it is also
possible that drugs which block several upregulated
chemokine receptors may also prove to be effective if they
are upstream of CCR2 expression.
In the course of these studies, we also noted that the PWT
to mechanical stimulation decreased bilaterally. The
degree of threshold change in the hindpaw contralateral
to the nerve injury was qualitatively similar but smaller in
magnitude, and briefer in time course, when compared
with the hindpaw ipsilateral to the lesion. This type of
bilateral hyperalgesia has previously been described in
other rodent models of neuropathic pain [58-67]. As such,
it is of interest to compare the LPC-induced peripheral
nerve pain model with previously described rodent
inflammatory pain models which demonstrated bilateral
tactile pain behavior [60] and contralateral changes in the
DRG [65,68]. Milligan et al. [69] suggested that this phe-
nomenon is likely due to changes in the spinal dorsal
horn. This type of spinal mechanism may drive both bila-
tateral pain sensitivity and contralateral DRG changes in
chemokines/receptors following unilateral sciatic nerve
demyelination by releasing cytokines from activated
microglia in the spinal cord dorsal horn following chronic
activity in injured DRG afferent neurons [70]. Spinal cord-
derived cytokines or growth factors such as TNF-α, IL-1β,
IL-6 and/or BDNF, may also directly signal contralateral
lumbar DRG neurons through receptors present on pri-
mary afferent central terminations [71,72]. Perhaps not
surprisingly, blockade of the action of TNF-α or inhibition
of glial metabolic activity can attenuate bilateral nocicep-
tive pain behavior [69,73], while the low dose administra-
tion of a gap junction protein decoupler only extinguishes
only contralateral pain behavior [74]. Although current
trends in pain research favor bilateral spinal cord glial
activation as a mechanism of central activation in the spi-
nal cord, it does not appear to be central to all pain con-
ditions [61]. It is also interesting to note in the context of
the present set of investigations that TNF-α can upregulate
MCP-1 expression by sensory neurons [75], further sup-
porting the possibility that it may function as an upstream
regulator of chemokine signaling in the DRG.
Alternatively, aspects of bilateral tactile hyperalgesia may
be due to spontaneous ectopic activity in A, but not C-fib-
ers. This type of ongoing ectopic hyperexcitability in pri-
mary sensory neurons post-injury can occur in both
injured neurons and adjacent, uninjured neurons
[20,37,76,77]. Changes necessary for this type of mecha-
nism implicate modification of the electrical properties of
the neurons [78-80]. Nerve demyelination in the mid-
thigh may effectively trigger just this type of change in the
primary sensory neuron (i.e. neurochemistry and physiol-
ogy of primary afferent neurons), which then contribute
to central sensitization and higher levels of nociceptive
sensory processing. Taken together, the evidence of
chronic changes in chemokine/receptor protein expres-
sion and the ability of certain chemokines to excite neuro-
nal subpopulations [6,8] is suggestive of a potential
scenario.
Another behavioral component commonly observed with
rodent pain models, especially those accompanied by
robust inflammatory responses, is the presence of thermal
hyperalgesia. Despite a presence of thermal hyperalgesia
in the mouse focal nerve demyelination model [12], the
rat nerve demyelination model does not exhibit changes
in response to temperature. Thermal hyperalgesia is
largely thought to be a pain-related symptom caused by
peripheral sensitization. The absence of thermal hyperal-
gesia would suggest that there is a lack of ongoing inflam-
matory mediator-initiated sensory neuron signaling. Lack
of thermal hyperalgesia in peripheral nerve injury models
of pain, although not common, include perineural gp-120
administration [81]; Bhangoo and White, unpublished
observations) acidic saline-induced hyperalgesia [63] andMolecular Pain 2007, 3:38 http://www.molecularpain.com/content/3/1/38
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chronic constriction injury performed in a 5-HT trans-
porter knockout mouse [82]. Lack of thermal hyperalgesia
in the model of muscle pain and CCI implicate central
descending mechanisms for the display of bilateral hyper-
algesia. It is possible that similar mechanisms are operat-
ing within the rat nerve demyelination injury model.
Taken together the data suggest that upregulation of
chemokine signaling by sensory neurons may help to
integrate several phenomena that account for changes in
the properties of peripheral nerves resulting in bilateral
pain hypersensitivity. The present results, together with
previous studies [3], suggest that the mode of injury may
determine which particular chemokines play a central role
in maintaining the neuropathic pain state. Chemokine
receptors may then represent novel targets for therapeutic
intervention in demyelination associated neuropathic
pain as well as other chronic pain states.
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